Indication
HRD
7 clinical trials
7 products
3 drugs
Clinical trial
A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
AMXI-5001Product
IDX-1197Clinical trial
An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients With Homologous Recombination Repair Mutated Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Cisplatin Based Regimen to Patients With Advanced Pancreatic Cancer and Homologous Recombination DeficiencyStatus: Recruiting, Estimated PCD: 2025-10-31
Drug
CisplatinClinical trial
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesStatus: Terminated, Estimated PCD: 2023-10-16
Product
NiraparibProduct
CarboplatinClinical trial
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyStatus: Active (not recruiting), Estimated PCD: 2025-05-15
Drug
AN0025Drug
DocetaxelProduct
RucaparibClinical trial
High Dose Testosterone + Carboplatin in Men With Advanced Prostate CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Product
Testosterone EnanthateClinical trial
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant MesotheliomaStatus: Recruiting, Estimated PCD: 2024-10-15
Product
Olaparib